📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis. (2012)

First Author: Mander AP

Attributed to: Hub in Trials Methodology Research (MRC Biostatistics Unit, Cambridge) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/pst.501

PubMed Identifier: 22232071

Publication URI: http://europepmc.org/abstract/MED/22232071

Type: Journal Article/Review

Volume: 11

Parent Publication: Pharmaceutical statistics

Issue: 2

ISSN: 1539-1604